Bristol Myers Squibb (NYSE:BMY) reported interim Phase 1 Breakfree-2 data on zola-cel CAR T therapy in multiple sclerosis. The readout showed early efficacy signals, including complete B cell depletion and patients remaining off disease modifying therapies. The company also reported…
Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis. The death occurred after Bristol Myers Squibb had already paused zola-cel studies following safety concerns at Novartis. Bristol Myers Squibb (BMS) has…
Data reinforce the potential for immune reset with zolacabtagene autoleucel to address an underlying cause of multiple sclerosis In the Breakfree-2 study, the majority of adverse events were brief and reversible, generally consistent with previously reported zola-cel Phase 1 clinical trial…
Bristol-Myers Squibb (BMY) shares were down 2% after the company said Friday that a patient with highly active relapsing multiple sclerosis in the phase 1 breakfree-2 study evalua... Oops, something went wrong U.S. markets close in 1h 28m Bristol-Myers Squibb Shares Fall After Patient Dealth…
Late-breaking Phase 2 global data presentation for pumitamig, a PD-L1 × VEGF-A bispecific immunomodulator, from ROSETTA Lung-107 in metastatic non-small cell lung cancer Late-breaking global Phase 2 data for pumitamig, an investigational PD-L1 x VEGF-A bispecific immunomodulator, being jointly developed with BioNTech Two…
By Caitlin Truesdale, Office of Marketing and Communications Students in the University of New Haven's Chemical and Biomolecular Engineering (CHME) program are earning recognition for their academic achievements and opening doors to new opportunities in research, energy, sustainability, and professional…
Bristol Myers Squibb (BMY), a biopharmaceutical company, announced Monday the topline results from its pivotal Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis (IPF). Admilparant is a potential first-in-class, orally administered lysophosphatidic acid receptor 1 (LPA1) antagonist. The trial…
Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP) shares fell 3% to $57.39 after positive results from a late-stage trial of an experimental cancer treatment raised questions about the market's reaction to the announcement. RYZ101 is a targeted radiopharmaceutical therapy developed by…
Bristol Myers Squibb (BMY) said Monday that an interim analysis of a phase 3 trial evaluating RayzeBio's radiopharmaceutical therapy RYZ101 met its primary endpoint. Bristol Myers... Oops, something went wrong U.S. markets close in 3h 40m Bristol Myers Squibb Says RayzeBio's Phase 3 Study for RYZ101 Meets…
Bristol Myers slips after mixed phase 3 admilparant IPF results; analysts weigh dose-response concerns and approval odds. Read more here. After opening Monday's trading session initially higher, Bristol Myers Squibb (BMY) shares are now down ~3% as the Street more fully digests…
What the labs are producing.
An article joins this feed when it matches these terms. Each one is also a search of its own.